Cell and Gene Therapy (CGT) Access Model (93.885)
Cell and Gene Therapy (CGT) Access Model (Assistance Listing 93.885) is run by the Centers for Medicare and Medicaid Services, part of the Department of Health and Human Services. It awarded $4.0 million in 8 grants from fiscal 2021 to 2025, about $499,750 per award on average. No funding opportunity is open on Grants.gov right now.
The typical award was $562,170. Half of the 8 awards fell between $291,736 and $702,018, and they ranged from $74,826 to $794,800.
- Awarded, FY 2021 to 2025$4.0 million
- Grant awards8
- Typical award$562,170
- Awarded in FY 2025$4.0 million
- Size rank1,661 of 1,823
- Type of assistanceCooperative agreement
Key findings
- It is the 1661st largest of 1,823 federal grant programs by five-year awards.
- The 8 largest recipients received 100% of the money.
- Awards went to recipients in 8 states and territories.
What the program funds
The Cell and Gene Therapy (CGT) Access Model aims to improve the lives of people with Medicaid living with rare and severe diseases by increasing access to potentially transformative treatments. It is a multi-year, voluntary model for states and manufacturers to test whether a CMS-led approach to developing and administering outcomes-based agreements (OBAs) for cell and gene therapies increases Medicaid beneficiaries’ access to innovative treatment, improves their health outcomes, and reduces health care costs and burden to state Medicaid programs. The initial focus of the model is on access to gene therapy treatments for people living with sickle cell disease, a genetic blood disorder. Manufacturers and state participants joined the model through a Request for Application (RFA) process. States begin participation between January 2025 and January 2026. The Notice of Funding Opportunity (NOFO) announced the opportunity to apply for Cooperative Agreement funding to support states’ participation in the CGT Access Model. Cooperative Agreement funding is intended to support state model implementation activities and to support states that take steps to improve equitable access to gene therapy and multi-disciplinary, comprehensive care in conjunction with the model test.
Open opportunities
No opportunity under this program is open or forecast on Grants.gov right now. Programs often post once a year, so the funding history below shows what to expect.
Rules from the program listing
Who can apply
Eligible applicants are States, the District of Columbia, and any U.S. Territory participating in the Medicaid Drug Rebate Program (MDRP). Eligible applicants must: • Apply to the State Request for Applications (RFA) by no later than March 14, 2025 • Apply to the Notice of Funding Opportunity (NOFO) by no later than March 14, 2025 • Sign a State Agreement with CMS by no later than June 1, 2025
What the money can and cannot pay for
Cooperative Agreement funding includes two distinct types of financial support: Implementation Funding and Milestone Funding. Implementation Funding is designed to support required and optional model activities that involve staff/contractor time and infrastructure costs, including partnerships with community-based organizations. Milestone Funding is designed to support states that successfully complete research projects related to increasing equitable access to SCD gene therapy and promoting multi-disciplinary, comprehensive care for beneficiaries with SCD who are considering or receiving SCD gene therapy. CMS prohibits the use of Cooperative Agreement funding to reimburse pre-award costs or to supplant existing state, local, tribal, or private funding of state costs. For a full list of all the applicable limitations on the use of funds, please review Sections D6 and F2 of the NOFO. These sections provide comprehensive guidelines to ensure the funds are used appropriately and in alignment with the overall objectives of the CGT Access Model.;
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. This program has MOE requirements, see funding agency for further details. N/A
Deadlines
Contact the headquarters or regional location, as appropriate for application deadlines Applications are due by February 28, 2025, 11:59 pm EST.
Award range and average, in the agency's words
CMS may award a maximum of $9.55 million in Cooperative Agreement award funding to each selected recipient over the course of up to 10.5 years. The Cooperative Agreement period of performance is anticipated to be July 1, 2025 to December 31, 2035.
Funding history and past recipients
From fiscal 2021 to 2025, Cell and Gene Therapy (CGT) Access Model (93.885) awarded $4.0 million across 8 grant awards, an average of $499,750 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| PA Department of Human Services | Pennsylvania | 1 | $794,800 |
| Illinois Department of Healthcare & Family Services | Illinois | 1 | $794,800 |
| Department of Social Services Connecticut | Connecticut | 1 | $671,090 |
| Department of Health Care Finance | District of Columbia | 1 | $565,398 |
| North Carolina Department of Health & Human Services | North Carolina | 1 | $558,941 |
| Mississippi Division of Medicaid | Mississippi | 1 | $314,400 |
| Health & Human Services, Rhode Island Executive Office of | Rhode Island | 1 | $223,745 |
| Human Services Vermont Agency of | Vermont | 1 | $74,826 |
Who usually wins
Almost all of the money went to state and local governments.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| State and local governments | 8 | $4.0 million | 100% |
By state
No state received $1 million or 10 awards from this program, so it has no state pages.
| State | Awards | Amount |
|---|---|---|
| Illinois | 1 | $794,800 |
| Pennsylvania | 1 | $794,800 |
| Connecticut | 1 | $671,090 |
| District of Columbia | 1 | $565,398 |
| North Carolina | 1 | $558,941 |
| Mississippi | 1 | $314,400 |
| Rhode Island | 1 | $223,745 |
| Vermont | 1 | $74,826 |